Maintenance. We are currently updating the site. Please check back shortly
Members login
  • TrustLaw
  • Members Portal
Subscribe Donate

Tampering in some US bottles of weight-loss drug Alli - Glaxo

Source: Reuters - Wed, 26 Mar 2014 21:09 GMT
Author: Reuters
hum-dis
Tweet Recommend Google + LinkedIn Email Print
Leave us a comment

(Updates with company statement, paragraphs 4-7)

March 26 (Reuters) - Some bottles of Alli, GlaxoSmithKline Plc's weight-loss drug sold over the counter in the United States, have been tampered with, and the Food and Drug Administration was investigating, the company said on Wednesday.

Consumers have reported that about 20 bottles bought in stores in seven mostly Southern states contained products other than the drug, GlaxoSmithKline said.

The company said the affected bottles from five lots of the drug could contain tablets and capsules of different shapes and colors. The actual drug is colored turquoise. The bottles could be unlabeled and the lot numbers might not match the numbers on the carton, GlaxoSmithKline said.

Glaxo spokeswoman Deborah Bolding said that so far there have been no reports of serious illness related to the products. The company has advised anyone who did take pills found to come from packages that had been tampered with to contact their doctor.

"We are doing an investigation to determine any further action," she said in a telephone interview.

FDA spokeswoman Tara Goodin confirmed by phone that the regulatory agency was also investigating the tampering.

Alli, which is sold by Glaxo's consumer healthcare business, is approved for use without a prescription for overweight adults, in conjunction with a low-fat diet.

Glaxo said the affected bottles were found in Alabama, Florida, Louisiana, Mississippi, New York, North Carolina and Texas. (Reporting By Vrinda Manocha and Deena Beasley; Editing by Ted Kerr and Jonathan Oatis)

We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of the Thomson Reuters Foundation. For more information see our Acceptable Use Policy.

comments powered by Disqus